MP16-04 TARGETING NEWLY IDENTIFIED ERβ/TGF-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA | Zendy

AI Assistant Blog Pricing

MP16-04 TARGETING NEWLY IDENTIFIED ERβ/TGF-β1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ERβ SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.